25514-67-4

Basic information

• Product Name: 5-CYANOGRAMINE
• Synonyms: 5-CYANOGRAMINE;3-(DIMETHYLAMINOMETHYL)-5-CYANOINDOLE;RARECHEM AH BS 0092;3-((dimethylamino)methyl)-1h-indole-5-carbonitril;3-(dimethylaminomethyl)-indole-5-carbonitril;3-(dimethylaminomethyl)indole-5-carbonitrile;3-[(Dimethylamino)methyl]-1H-indole-5-carbonitrile
• CAS NO: 25514-67-4
• Molecular Formula: C12H13N3
• Molecular Weight: 199.25
• Mol File: 25514-67-4.mol

Chemical Properties

• Boiling Point: 368.2°Cat760mmHg
• Flash Point: 176.5°C
• Appearance: /
• Density: 1.17g/cm³
• Vapor Pressure: 1.3E-05mmHg at 25°C
• Refractive Index: 1.634
• CAS DataBase Reference: 5-CYANOGRAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CYANOGRAMINE(25514-67-4)
• EPA Substance Registry System: 5-CYANOGRAMINE(25514-67-4)

Safety Data

• Hazardous Substances Data: 25514-67-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-CYANOGRAMINE is used as a pharmaceutical excipient for its ability to enhance the solubility, stability, and bioavailability of active pharmaceutical ingredients. Its unique chemical structure allows it to interact with a wide range of compounds, making it a versatile and valuable component in the development of new drugs.
Used in Research and Development:
5-CYANOGRAMINE is used as a research compound for studying the structure-activity relationships of tryptamines and their analogs. Its unique properties make it an important tool in the development of new drugs with potential therapeutic applications in various medical fields.
Used in Drug Delivery Systems:
5-CYANOGRAMINE can be used as a component in drug delivery systems to improve the targeted delivery of therapeutic agents. Its ability to interact with various biopolymers and macromolecules can be exploited to enhance the specificity and efficacy of drug delivery, potentially leading to improved treatment outcomes for patients.
Used in Neuropharmacology:
5-CYANOGRAMINE may have potential applications in neuropharmacology, as it is a substituted tryptamine with known effects on the central nervous system. Further research is needed to fully understand its potential therapeutic applications in this field.
Used in Psychedelic-Assisted Therapy:
5-CYANOGRAMINE, as a derivative of DMT, may have potential applications in psychedelic-assisted therapy. Its unique properties could be explored for their potential to enhance the therapeutic effects of psychedelic substances in the treatment of various mental health conditions, such as depression, anxiety, and post-traumatic stress disorder (PTSD). However, more research is needed to fully understand its potential in this area.

InChI:InChI=1/C12H13N3/c1-15(2)8-10-7-14-12-4-3-9(6-13)5-11(10)12/h3-5,7,14H,8H2,1-2H3

Upstream product

• 30354-18-8 N,N-dimethyl(methylene)ammonium chloride 
• 261177-22-4 1-Diethoxymethylindole-5-carbonitrile 
• 15861-24-2 1H-indole-5-carbonitrile 
• 50-00-0 formaldehyd 
• 124-40-3 dimethyl amine 
• 497-19-8 sodium carbonate 

Downstream Products

• 17380-18-6 3-formyl-1H-indole-5-carbonitrile 

Relevant articles and documents

Rhodium-Catalyzed Enantioselective Cyclization of 3-Allenyl-indoles: Access to Functionalized Tetrahydrocarbazoles

A highly selective rhodium-catalyzed cyclization of tethered 3-allenylindoles is reported. In a smooth reaction, 1-vinyltetrahydrocarbazoles are obtained in excellent yields and enantioselectivities. Aside from a great functional group tolerance, this method requires neither the Schlenk technique nor the use of anhydrous solvents. Preliminary mechanistic investigations proved that the reaction proceeds via an intermediary formed spiroindolenine which rapidly undergoes an acid-catalyzed stereospecific migration.

Rhodium-Catalyzed Diastereo- And Enantioselective Tandem Spirocyclization/Reduction of 3-Allenylindoles: Access to Functionalized Vinylic Spiroindolines

A highly selective rhodium-catalyzed tandem spirocyclization/reduction of 3-allenylindoles is reported. By employing a Hantzsch ester as reductant, vinylic spiroindolines are obtained in excellent yields as well as diastereo- and enantioselectivity. In addition, the reaction's synthetic utility is highlighted by broad functional group compatibility and exemplified by a gram scale reaction with subsequent assorted transformations.

INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION

The present invention relates to a method for alleviation, prevention, and treatment of anxiety, depression, and sexual dysfunction by administering certain indolylalkyl derivatives of pyrimidinylpiperazine or metabolites thereof. A preferred embodiment is of the following formula:

REACTIVE HETEROCYCLIC DERIVATIVES AND METHODS FOR THEIR SYNTHESIS AND USE

The present invention describes molecules having a core structure that is an indole or an indolene that is modified to provide a functional moiety, and methods for their synthesis and use. Such functionalized heterocyclic derivatives may be used in a variety of assay formats.

Traceless linking of indoles: General methodology and application to solid phase supported Mannich and Stille reactions

Transacetalization reaction of the diethoxymethyl (DEM) protected indoles 2a,b,d,e with the polymer bound glycerol derivative 3 resulted in formation of the immobilized indoles 4a,b,d,e. Selective indole- functionalizations as well as quantitative and traceless cleavage could be demonstrated.

Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkylpiperazines

A series of novel alkoxypyridin-4-yl and alkoxypyrimidin-4-yl derivatives of indol-3-ylalkylpiperazines of Formula I are intended to be useful agents STR1 for alleviation of vascular headache on the basis of their potent affinity and agonist activity at 5-HT1D binding sites.

INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE FOR TREATING VASCULAR HEADACHE

A series of novel indol-3-ylalkyl derivatives of alkoxypyrimidinylpiperazines are disclosed as Formula I. STR1 These compounds are intended to be useful agents for alleviation of vascular headache on the basis of their potent affinity and agonist activity at 5-HT1D binding sites.